![Weekly Enforcement Report: Medical Equipment & Kickbacks](https://www.g2intelligence.com/wp-content/uploads/2023/01/Jan25-2023.News_.WeeklyEnforcementReport.MedEqptSchemes-iStock-1800x1250-1-1080x675.jpg)
Weekly Enforcement Report: Medical Equipment & Kickbacks
While labs were absent from recent enforcement actions, last week saw kickback schemes involving DME companies and a medical device company.
While labs were absent from recent enforcement actions, last week saw kickback schemes involving DME companies and a medical device company.
While most recent cases were the usual FCA and kickback-related issues, one involved the mischarging of federal grants by two biotech companies and their co-founder.
In our latest roundup, schemes involving cancer genetic testing and kickbacks remain the most common, but there were some surprises.
Key cases over the last month include a CGx testing kickback scheme, false billing, and violations of a non-compete clause and HIPAA.
Last week’s cases saw a major false claims-related settlement, as well as many kickback-related schemes.